AR123523A1 - Nuevos anticuerpos anti-a2ap y usos de los mismos - Google Patents
Nuevos anticuerpos anti-a2ap y usos de los mismosInfo
- Publication number
- AR123523A1 AR123523A1 ARP210102562A ARP210102562A AR123523A1 AR 123523 A1 AR123523 A1 AR 123523A1 AR P210102562 A ARP210102562 A AR P210102562A AR P210102562 A ARP210102562 A AR P210102562A AR 123523 A1 AR123523 A1 AR 123523A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- binding fragment
- antibody
- isolated antibody
- isolated
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 14
- 102000036639 antigens Human genes 0.000 abstract 14
- 108091007433 antigens Proteins 0.000 abstract 14
- 239000012634 fragment Substances 0.000 abstract 13
- 210000004027 cell Anatomy 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 102100035991 Alpha-2-antiplasmin Human genes 0.000 abstract 3
- 101000783712 Homo sapiens Alpha-2-antiplasmin Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical group 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010051055 Deep vein thrombosis Diseases 0.000 abstract 1
- 108010088842 Fibrinolysin Proteins 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 208000010378 Pulmonary Embolism Diseases 0.000 abstract 1
- 206010037459 Pulmonary venous thrombosis Diseases 0.000 abstract 1
- 206010059054 Shunt thrombosis Diseases 0.000 abstract 1
- 206010053648 Vascular occlusion Diseases 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940012957 plasmin Drugs 0.000 abstract 1
- 210000001236 prokaryotic cell Anatomy 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 208000021331 vascular occlusion disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Un anticuerpo aislado o fragmento de unión a antígeno del mismo capaz de unirse a A2AP e inhibir la actividad de A2AP, en donde dicho anticuerpo aislado o fragmento de unión a antígeno del mismo no inhibe la actividad de plasmina. Reivindicación 12: Un anticuerpo aislado o fragmento de unión a antígeno del mismo que compite con el anticuerpo aislado o fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 - 11 por la unión a A2AP. Reivindicación 13: Un conjugado de anticuerpo, que comprende el anticuerpo aislado o el fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 12. Reivindicación 14: Una secuencia de ácido nucleico aislada que codifica el anticuerpo o el fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 12. Reivindicación 15: Un vector que comprende una secuencia de ácido nucleico de acuerdo con la reivindicación 14. Reivindicación 16: Una célula aislada que expresa el anticuerpo o fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 12 y/o que comprende el ácido nucleico de acuerdo con la reivindicación 14 o el vector de acuerdo con la reivindicación 15. Reivindicación 17: La célula aislada de acuerdo con la reivindicación 16, en donde dicha célula es una célula procariota o eucariota. Reivindicación 18: Un método para producir el anticuerpo aislado o fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 12 que comprende el cultivo de la célula de acuerdo con cualquiera de las reivindicaciones 16 ó 17 y opcionalmente purificación del anticuerpo o fragmento de unión a antígeno. Reivindicación 19: Una composición farmacéutica que comprende el anticuerpo aislado o el fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 12 o el anticuerpo conjugado de acuerdo con la reivindicación 13 y opcionalmente uno o más excipientes farmacéuticamente aceptables. Reivindicación 20: Un anticuerpo aislado o fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 12 o el conjugado de acuerdo con la reivindicación 13 o la composición farmacéutica de acuerdo con la reivindicación 19 para uso en el tratamiento o profilaxis de una enfermedad. Reivindicación 22: Un anticuerpo aislado o fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 12 o el conjugado de acuerdo con la reivindicación 13 o la composición farmacéutica de acuerdo con la reivindicación 19 para uso en el tratamiento o profilaxis de trastornos o enfermedades asociadas con eventos isquémicos debidos a oclusión vascular parcial o completa, tal como accidente cerebrovascular isquémico, síndrome coronario agudo, enfermedad arterial periférica, infarto de miocardio, trombosis venosa profunda, embolia pulmonar, trombosis venosa o trombosis de derivación. Reivindicación 23: Un anticuerpo aislado o fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 12 o el conjugado de acuerdo con la reivindicación 16 o la composición farmacéutica de acuerdo con la reivindicación 19 para uso en combinación simultánea, separada o secuencial con uno o más compuestos terapéuticamente activos adicionales, particularmente seleccionados entre inhibidores de la cascada de la coagulación, anticoagulantes e inhibidores de la agregación plaquetaria.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20196259 | 2020-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123523A1 true AR123523A1 (es) | 2022-12-14 |
Family
ID=72521424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102562A AR123523A1 (es) | 2020-09-15 | 2021-09-15 | Nuevos anticuerpos anti-a2ap y usos de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20240010750A1 (es) |
| EP (1) | EP4214241A2 (es) |
| JP (2) | JP7454106B2 (es) |
| KR (1) | KR20230069171A (es) |
| CN (1) | CN116249719A (es) |
| AR (1) | AR123523A1 (es) |
| AU (1) | AU2021343834A1 (es) |
| BR (1) | BR112023002800A2 (es) |
| CA (1) | CA3194792A1 (es) |
| IL (1) | IL301307A (es) |
| MX (1) | MX2023002984A (es) |
| PE (1) | PE20240214A1 (es) |
| TW (1) | TW202227505A (es) |
| WO (1) | WO2022058261A2 (es) |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5582862A (en) * | 1988-04-04 | 1996-12-10 | General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
| JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質／（ポリ）ペプチドライブラリー |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| JP2001515345A (ja) | 1996-09-20 | 2001-09-18 | ザ・ジェネラル・ホスピタル・コーポレイション | アルファ―２―抗プラスミンに対する抗体を用いてフィブリン溶解を増進するための組成物と方法 |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| CA2838062C (en) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
| AU2005230848B9 (en) | 2004-03-31 | 2011-06-02 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| WO2008112640A2 (en) | 2007-03-09 | 2008-09-18 | Sinomab Bioscience Limited | Construction and use of a functionally human antibody library with maximized repertoire diversity |
-
2021
- 2021-09-13 MX MX2023002984A patent/MX2023002984A/es unknown
- 2021-09-13 BR BR112023002800A patent/BR112023002800A2/pt unknown
- 2021-09-13 CN CN202180062581.XA patent/CN116249719A/zh active Pending
- 2021-09-13 US US18/026,089 patent/US20240010750A1/en active Pending
- 2021-09-13 TW TW110133977A patent/TW202227505A/zh unknown
- 2021-09-13 KR KR1020237012503A patent/KR20230069171A/ko unknown
- 2021-09-13 CA CA3194792A patent/CA3194792A1/en active Pending
- 2021-09-13 WO PCT/EP2021/075038 patent/WO2022058261A2/en active Application Filing
- 2021-09-13 IL IL301307A patent/IL301307A/en unknown
- 2021-09-13 PE PE2023001168A patent/PE20240214A1/es unknown
- 2021-09-13 AU AU2021343834A patent/AU2021343834A1/en active Pending
- 2021-09-13 EP EP21773115.7A patent/EP4214241A2/en active Pending
- 2021-09-13 JP JP2023516588A patent/JP7454106B2/ja active Active
- 2021-09-15 AR ARP210102562A patent/AR123523A1/es unknown
-
2023
- 2023-06-06 US US18/329,700 patent/US20240034810A1/en active Pending
- 2023-11-30 US US18/525,736 patent/US20240166766A1/en active Pending
-
2024
- 2024-03-08 JP JP2024035682A patent/JP2024063234A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022058261A3 (en) | 2022-06-16 |
| CA3194792A1 (en) | 2022-03-24 |
| US20240166766A1 (en) | 2024-05-23 |
| WO2022058261A2 (en) | 2022-03-24 |
| EP4214241A2 (en) | 2023-07-26 |
| AU2021343834A1 (en) | 2023-04-13 |
| CN116249719A (zh) | 2023-06-09 |
| US20240034810A1 (en) | 2024-02-01 |
| JP2023541179A (ja) | 2023-09-28 |
| PE20240214A1 (es) | 2024-02-16 |
| KR20230069171A (ko) | 2023-05-18 |
| MX2023002984A (es) | 2023-04-10 |
| IL301307A (en) | 2023-05-01 |
| TW202227505A (zh) | 2022-07-16 |
| JP2024063234A (ja) | 2024-05-10 |
| JP7454106B2 (ja) | 2024-03-21 |
| BR112023002800A2 (pt) | 2023-03-21 |
| US20240010750A1 (en) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ellison-Hughes et al. | The role of MSC therapy in attenuating the damaging effects of the cytokine storm induced by COVID-19 on the heart and cardiovascular system | |
| Chatterjee et al. | Platelet‐derived CXCL12 (SDF‐1α): basic mechanisms and clinical implications | |
| Langer et al. | Platelet derived bFGF mediates vascular integrative mechanisms of mesenchymal stem cells in vitro | |
| AR111203A1 (es) | Inmunoconjugados | |
| GT200900029A (es) | Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4 | |
| Xiang et al. | Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic | |
| CL2021003080A1 (es) | Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813) | |
| HRP20220910T1 (hr) | Nova anti-humana gpvi antitijela i njihove uporabe | |
| Sarich et al. | Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis‐mediated conditions | |
| Yip et al. | Tissue plasminogen activator enhances mobilization of endothelial progenitor cells and angiogenesis in murine limb ischemia | |
| Lorga Filho et al. | Brazilian guidelines on antiplatelet and anticoagulant agents in cardiology | |
| CN113663077B (zh) | 经由自体干细胞动员的创伤愈合 | |
| Cañas | Brainstem ischemic stroke after to Bothrops atrox snakebite | |
| Špinar et al. | SAVOR-TIMI 53-saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | |
| AR123523A1 (es) | Nuevos anticuerpos anti-a2ap y usos de los mismos | |
| RU2007136791A (ru) | Новые гибридные белки-активаторы плазминогена, используемые в качестве тромболитических средств | |
| CO2021008338A2 (es) | Polipéptidos de activador de plasminógeno, tipo urocinasa, modificados y métodos de uso | |
| Pesavento et al. | Prevention and treatment of the post-thrombotic syndrome and of the chronic thromboembolic pulmonary hypertension | |
| AR123861A1 (es) | Politerapia de antagonistas de unión al eje pd-1 e inhibidores de lrrk2 | |
| Riva et al. | Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: The case of venous thromboembolism | |
| Liu et al. | Improving treatment for acute ischemic stroke—Clot busting innovation in the pipeline | |
| JP7231543B2 (ja) | 心不全および心臓虚血再灌流障害の治療 | |
| Witkowski et al. | Non-vitamin K antagonist oral anticoagulants in the treatment of coronary and peripheral atherosclerosis | |
| Zimarino et al. | Facilitated PCI: rationale, current evidence, open questions, and future directions | |
| EA201800084A1 (ru) | НОВЫЕ АМИДИНЫ-ИНГИБИТОРЫ ФАКТОРА Ха |